Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04624204 · ClinicalTrials.gov registry record · Phase 3
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
A Phase 3 study of Small-cell Lung Cancer, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 3
- Development phase
- 672
- Enrollment target
- 20
- Study locations
NCT04624204 is a Phase 3 study of Small-cell Lung Cancer that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 672 participants, above the 224-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (200% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT04624204, a Phase 3 study of Small-cell Lung Cancer, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 672 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and radiation treatment (CRT), can be effective in treating LS-SCLC. The researchers want to know if participants who receive CRT and pembrolizumab, with or without olaparib, have a longer overall survival compared to participants who only receive CRT.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab 200 mg
- BIOLOGICAL Pembrolizumab 400 mg
- DRUG Pembrolizumab placebo (saline)
- DRUG Olaparib 300 mg BID
Study Locations (20)
New Jersey
- Memorial Sloan Kettering - Basking Ridge ( Site 0133) - Basking Ridge
- John Theurer Cancer Center ( Site 0064) - Hackensack
- Memorial Sloan Kettering - Monmouth ( Site 0135) - Middletown
- Memorial Sloan Kettering - Bergen ( Site 0130) - Montvale
- Rutgers Cancer Institute of New Jersey ( Site 0123) - New Brunswick
New York
- Memorial Sloan Kettering- Commack ( Site 0132) - Commack
- Memorial Sloan Kettering - Westchester-Thoracic Oncology ( Site 0134) - Harrison
- Memorial Sloan Kettering Cancer Center ( Site 0069) - New York
Arizona
- Ironwood Cancer & Research Centers ( Site 0007) - Chandler
California
- Loma Linda University Cancer Center ( Site 0011) - Loma Linda
District of Columbia
- Georgetown University ( Site 0017) - Washington D.C.
Florida
- Moffitt Cancer Center ( Site 0137) - Tampa
Illinois
- University of Chicago Medical Center ( Site 0136) - Chicago
Indiana
- Fort Wayne Medical Oncology and Hematology ( Site 0034) - Fort Wayne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 672 participants |
| Start Date | 2020-12-08 |
| Est. Completion | 2027-10-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04624204
The ClinicalTrials.gov registry entry for NCT04624204 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 672 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 224-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (200% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab 200 mg is the first listed.
NCT04624204 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New Jersey, New York, Arizona.
Frequently Asked Questions
What is clinical trial NCT04624204 about?
NCT04624204 is a clinical study titled "Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)". Researchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and radiation treatment ...
What is the current status of trial NCT04624204?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 672 participants. The study started on 2020-12-08. Estimated completion is 2027-10-28.
What conditions does trial NCT04624204 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer.
What interventions are being tested in trial NCT04624204?
The interventions under investigation include: Pembrolizumab 200 mg (BIOLOGICAL), Pembrolizumab 400 mg (BIOLOGICAL), Pembrolizumab placebo (saline) (DRUG), Olaparib 300 mg BID (DRUG).
Who is sponsoring clinical trial NCT04624204?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04624204 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
RECRUITING · Phase 3
-
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
RECRUITING · Phase 3
-
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
RECRUITING · Phase 3
-
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
RECRUITING · Phase 3
-
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
ACTIVE NOT RECRUITING · Phase 3
-
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.